Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age4-9
SponsorOctober University for Modern Sciences and Arts

About this trial

Despite the benefit of formocresol, there are toxic effects allergic reactions and local soft and hard tissue necrosis have been reported when such formaldehyde compounds were used clinically, however, the adverse effect of the clinically used of this compound are not widely reported. It has been stated that it has a side effect on the permanent successor although it results as a successful technique for the treatment of the primary teeth

Eligibility criteria

Qualifiers

4 -9 years old

Primary molars with no spontaneous or provoked pain

Primary molars with at least two-thirds of the root length were still present.

Primary molars with no sign of internal or other kinds of root or bone resorption.

Disqualifiers

Patients with systemic diseases (congenital or rheumatic heart disease, hepatitis, nephritis, tumor, cyclic neutropenia, leukemia, and children on long-term corticosteroid therapy).

Un-cooperative patients.

Un-restorable primary molars (Grossly broken-down primary molars that have decay extending way under the gingiva and tooth with root caries).

Trial design

Treatments tested in this trial

  • A cotton pellet moistened with full-strength FC
  • Neo-Putty

Treatment groups

44 Participants
are divided into 2 treatment groups